Mike Nash

Pharmacokinetics of the novel, high-affinity and selective dopamine D3 receptor antagonist SB-277011 in rat, dog and monkey:<i>in vitro/in vivo</i>correlation and the role of aldehyde oxidase

Nigel Austin, S. J. Baldwin, Leanne Cutler et al. · Xenobiotica · 2001 · 63 citations

Disposition and Metabolism of [14C]SB-649868, an Orexin 1 and 2 Receptor Antagonist, in Humans

Cecilia Renzulli, Mike Nash, Mark Wright et al. · Drug Metabolism and Disposition · 2010 · 29 citations

Metabolism and disposition of¹⁴C-granisetron in rat, dog and man after intravenous and oral dosing

S. E. Clarke, Nigel Austin, J. C. Bloomer et al. · Xenobiotica · 1994 · 29 citations

Assessment of potential drug interactions by characterization of human drug metabolism pathways using non‐invasive bile sampling

Jackie C. Bloomer, Mike Nash, Alison Webb et al. · British Journal of Clinical Pharmacology · 2012 · 20 citations · Full text

Disposition and Metabolism of Darapladib, a Lipoprotein-Associated Phospholipase A2 Inhibitor, in Humans

Mehul Dave, Mike Nash, Graeme Young et al. · Drug Metabolism and Disposition · 2013 · 17 citations